Showing results for: "pharmaceutical nanotechnology" (20 results)
Nanotechnology is having a big impact on pharmaceutical sciences, and drug delivery systems are one area where this is most evident. Compared to conventional medication delivery methods, nanoparticles provide a number of benefits, including increased effectiveness and fewer adverse drug reactions.
How a 150-year-old food industry technique became essential for creating stable biologics and inhaled medicines, transforming liquid drugs into life-saving powders.
Messenger RNA (mRNA) vaccines represent one of the most significant scientific advances in modern therapeutics. Unlike conventional vaccines that use weakened or inactivated pathogens, mRNA vaccines deliver genetic instructions that enable host cells to synthesize a target antigen and stimulate an immune response.
Smart nanoparticles are an exciting step forward in modern medicine especially nanomedicine. They help doctors be more precise in cancer treatment.
Too big, it hits your throat. Too small, you exhale it. The sweet spot delivers drugs exactly where they're needed.
Today, generalized anxiety disorder is affecting millions of Americans. The disorder usually traps the sufferers in cycles of fear and isolation in a way that even standard treatments cannot relieve completely. UCSF neuroscientist Jennifer Mitchell, PhD, is testing a surprising brand-new approach that can ease symptoms of generalized anxiety disorder by reshaping how the brain thinks and feels.
Natural polysaccharides like locust bean gum and chitosan are replacing lactose as safer, more effective carriers for inhaled medications and vaccines.
Selective oxidation reactions are central to modern biochemistry. They enable the controlled introduction of oxygen into organic molecules, a key step in the synthesis of pharmaceuticals and fine chemicals. However, many of the enzymatic systems traditionally used for these transformations are complex and difficult to implement in practice.
(DCTs) are redefining how pharmaceutical studies are designed, conducted, and analyzed by moving away from traditional site-centric models toward patient-centric, digitally enabled trial ecosystems.
Modern healthcare is undergoing a silent revolution. Now to treat a disease in the healthcare system, there is no longer a need to wait for symptoms to appear.
Plant mucilage is a thick, glue-like substance produced by plants that helps with seed germination, water and nutrient storage, and defense. Flax and chia seeds are rich sources of mucilage and have various applications in the food and pharmaceutical industries.
Biologics have transformed the management of chronic and life-threatening diseases such as cancer, autoimmune disorders, and metabolic conditions. However, their complexity, high production costs, and limited affordability continue to challenge healthcare systems worldwide.
Healthcare is changing faster than ever before. Thanks to breakthroughs in artificial intelligence (AI), genomics, and wearable technology, medicine is entering the era of smart health, where data, devices, and biology work together to create care tailored to the individual.
Inhaled antibiotics deliver drugs directly to lung infections, achieving better results with fewer side effects, which is a game-changer in fighting resistance.
Why is mucus the biggest obstacle to lung drug delivery? Explore the mucosal barrier science reshaping how we design inhaled medicines and vaccines.
Scientific advancement drives growth, productivity, and long-term global competitiveness in advanced economies.
This article aims to demystify the anatomy of a clinical trial protocol, peeling back the technical layers to reveal how scientific rigor is converted into medical progress. At ScientistsHub, we often ask: How do we ensure that a medical breakthrough is not just a stroke of luck, but a repeatable, verifiable victory for human health? The answer is found in the design. To truly appreciate the result of any trial, one must first master the architecture of the inquiry.
Vaccines need precise temperature control to work but maintaining the cold chain wastes half of all doses globally. New thermostable formulations could change everything.
This article will unlock that box, exploring the crucial process of translating complex clinical trial evidence into clear, understandable information for everyone. We'll journey from the surprising origins of clinical trials to the modern-day push for transparency, and discover why making science accessible is not just a convenience, but a necessity for public trust and informed health decisions.
Disorders of Gut–Brain Interaction (DGBIs), such as Functional Dyspepsia (FD) and Irritable Bowel Syndrome (IBS), present a formidable clinical impasse due to their profoundly heterogeneous and multifactorial nature.
